Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, Chun‐Ming Tsai et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 1.6k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James Chih‐Hsin Yang, Yi‐Long Wu, Lecia V. Sequist et al.|The Lancet Oncology|2015Cited by 980
Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancerSarayut Lucien Geater, Pritsana Raungrut|Oncology Letters|2021Cited by 9